Pharmacy Website
Clinic Website

Intelligence » Top Posts » Last Week

Subscribe to get latest posts via email or subscribe to a RSS feed.

Drinking Two or More Diet Sodas a Day Increases Likelihood of Strokes, Heart-Attacks, American Heart Association Says

Thursday, February 14, 2019 -- Women who drank two or more artificially sweetened drinks had a 23% higher risk of strokes, according to the American Heart Association.

We now have an outbreak': 8 cases of measles confirmed in Vancouver

Friday, February 15, 2019 -- Vancouver health officials say they've identified eight cases of measles in the city in recent weeks.

Philippines revokes Sanofi's product license for dengue vaccine

Tuesday, February 19, 2019 -- The Philippines has permanently halted the sale, distribution and marketing of Sanofi's dengue vaccine in the country after the French drug maker failed to meet the directives of regulators.

Common herbicide found to increase the risk of Non-Hodgkin Lymphoma

Friday, February 15, 2019 -- A new study has shown that the herbicide glyphosphate, could increase the risk of Non-Hodgkin Lymphoma by 41 percent among those who are exposed.

Researchers find clues that depression may speed brain aging

Friday, February 15, 2019 -- Depression has long been linked to certain cognitive problems, and depression late in life even may be a risk factor for the development of Alzheimer's. Yet how depression might harm cognition isn't clear.

Pfizer-Lilly drug shown to help reduce back pain in late-stage trial

Tuesday, February 19, 2019 -- A non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co succeeded in reducing chronic low back pain when used in a stronger dose, results from a late-stage study showed on Tuesday.

Merck plans trio of Phase 3 Keytruda studies in prostate cancer

Thursday, February 14, 2019 -- Announcement of the trials comes as the drugmaker unveiled mid-stage data from testing of several Keytruda combos in the common cancer type.

Split Dosing of Darzalex Over Consecutive Days Approved by FDA for Multiple Myeloma Patients

Monday, February 18, 2019 -- The U.S. Food and Drug Administration has approved a new dosing regimen for the multiple myeloma treatment Darzalex (daratumumab), allowing doctors to split the first infusion over two consecutive days. The approval is based on data from the EQUULEUS Phase 1b trial (NCT01998971), where the split dosing lead to similar safety and pharmacokinetics — the way a compound is absorbed, […] The post Split Dosing of Darzalex Over Consecutive Days Approved by FDA for Multiple Myeloma Patients appeared first on Myeloma Research News.

Breast pumps could be transmitting asthma-causing bacteria in babies, finds study

Thursday, February 14, 2019 -- Mothers across the world use breast pumps to pump put the milk that is fed to their babies. A new study has revealed that these pumps may not be safe and may be contaminated with bacteria that can cause asthma in the babies later in life. The results of this study were published in the latest issue of the journal Cell Host & Microbe.

Celiac disease may be caused by gastrointestinal infection in childhood

Friday, February 15, 2019 -- A new study has found that a childhood stomach bug may be the cause of celiac disease later in life. The findings could pave the way for a vaccine to protect against the disease.

AI examines artery calcium deposits to assess heart disease risk

Friday, February 15, 2019 -- Researchers have developed a machine learning system that examines artery calcium deposits in the heart to assess heart disease risk.Read More

New therapeutic molecules show promise in reversing memory loss related to depression, aging

Friday, February 15, 2019 -- New therapeutic molecules developed at Toronto's Centre for Addiction and Mental Health show promise in reversing the memory loss linked to depression and aging.

Novel immunotherapy prevents cervical, lung cancer in mice

Friday, February 15, 2019 -- Researchers at the University of Louisville were testing a protein-based molecule they originally developed to boost the power of T cells in treating cancer when they made a surprising discovery: The drug protected normal mice from developing cancer in the first place.

FDA approves Keytruda for adjuvant treatment of melanoma

Tuesday, February 19, 2019 -- The FDA approved pembrolizumab for adjuvant treatment of patients who have melanoma with lymph node involvement who underwent complete resection.This is the first U.S. approval for pembrolizumab (Keytruda, Merck) — an anti-PD-1 therapy — in the adjuvant setting and the fourth for skin cancer treatment.The FDA based the approval on results of the randomized phase 3 EORTC1325/KEYNOTE-054 trial, which included 1,019 patients (median age, 54 years; range, 19-88; 62% men) with completely resected stage IIIA (16%), IIIB (46%) or IIIC melanoma. All patients had ECOG performance status of

Single Dose of Gene Therapy AMT-061 Proves Effective in Hemophilia B

Thursday, February 14, 2019 -- A single administration of AMT-061, an investigational gene therapy for people with severe and moderately severe hemophilia B, increased therapeutic levels of factor IX (FIX) in all patients enrolled in uniQure’s ongoing Phase 2b trial, the company announced. Ultimately, this trial’s purpose is to confirm the dose of AMT-061 for the pivotal Phase 3 HOPE-B […] The post Single Dose of Gene Therapy AMT-061 Proves Effective in Hemophilia B appeared first on Hemophilia News Today.

Asthma classes in school may help reduce attacks

Friday, February 15, 2019 -- (Reuters Health) - School-age children with asthma who receive education on managing the condition may have fewer attacks, emergency room visits and hospitalizations than those who don't get such classes, a recent study suggests.

Humira Reduces Early Ulcerative Colitis Features, Trial Analysis Shows

Monday, February 18, 2019 -- AbbVie‘s Humira (adalimumab) reduces early tissue inflammation, rectal bleeding, and stool frequency in patients with ulcerative colitis, according to a post-hoc analysis of two Phase 3 trials. Findings were published in the study, “Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in 2 Clinical Trials,” were […] The post Humira Reduces Early Ulcerative Colitis Features, Trial Analysis Shows appeared first on IBD News Today.

Reprogramming pancreatic cells into insulin makers to treat diabetes

Thursday, February 14, 2019 -- Scientists are keen to find methods for regenerating insulin-producing beta cells to treat diabetes. Now, researchers at the University of Geneva have converted other pancreatic cells into cells that can secret insulin, and they have shown promising results in treating mouse models of diabetes.

Bright sunlight exposure may decrease risk for type 2 diabetes, CVD

Tuesday, February 19, 2019 -- Healthy, middle-aged adults exposed to more bright sunlight in the 7 days before providing a blood sample had lower levels of markers indicating risk for insulin resistance and dyslipidemia vs. adults exposed to less sunlight, according to findings published in The Journal of Clinical Endocrinology & Metabolism.“Spending more time outdoors in the sun might be associated with health benefits,” Constantinos Christodoulides, MD, PhD, a university research lecturer and honorary consultant in diabetes and endocrinology at the Oxford Centre for Diabetes, Endocrinology and Metabolism

Fatty liver increases diabetes risk for adults without obesity

Thursday, February 14, 2019 -- Nonalcoholic fatty liver disease is an independent risk factor for diabetes development in adults without obesity, according to findings published in Nutrition, Metabolism and Cardiovascular Diseases.“Although it is very well-established that nonalcoholic fatty liver disease (NAFLD) occurs frequently in obese subjects, it is now becoming clear that NAFLD also occurs in a substantial proportion of nonobese individuals,” Ki-Chul Sung, MD, PhD, of the division of cardiology at Kangbuk Samsung Hospital in Seoul, South Korea, and colleagues wrote. “The mechanisms by which